ArticleCritical care (London, England)2011
A dynamic view of mHLA-DR expression in management of severe septic patients.
Article in Critical care (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Predictive Value of Perioperative Systemic Inflammation Response Index Dynamics for Postoperative Pulmonary Infection Following Esophagectomy: A Multicenter Retrospective Cohort Study.Journal of inflammation research · 2026Article
- Prognostic Value of Peripheral Blood nCD64 Index, mHLA-DR, and CD14Journal of inflammation research · 2025Article
- Monocytic HLA-DR Expression in Immune Responses of Acute Pancreatitis and COVID-19.International journal of molecular sciences · 2023Review
- Expert consensus on the monitoring and treatment of sepsis-induced immunosuppression.Military Medical Research · 2022Article
- Functional Ex Vivo Testing of Alveolar Monocytes in Patients with Pneumonia-Related ARDS.Cells · 2021Observational
- Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19.Journal of clinical medicine · 2021Review
- Point-of-critical-care diagnostics for sepsis enabled by multiplexed micro and nanosensing technologies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Alveolar compartmentalization of inflammatory and immune cell biomarkers in pneumonia-related ARDS.Critical care (London, England) · 2021Observational
- Increases in inflammatory and CD14Critical care (London, England) · 2018Observational
- Source of Circulating Pentraxin 3 in Septic Shock Patients.Frontiers in immunology · 2018Observational
- Immunological monitoring to prevent and treat sepsis.Critical care (London, England) · 2013Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence suggests that the secondary phase of sepsis (that is, after the first proinflammatory hours) is characterized by the occurrence of a systemic failure of the immune system. In the most immunodepressed patients, therapies could be used to restore normal immune functions. However, biomarkers need to be developed to beforehand specifically identify these patients. Of these biomarkers, diminished monocyte HLA-DR expression has rapidly become the most popular. Herein, novel perspectives regarding monocyte HLA-DR assessed as a dynamic parameter in septic patients will be discussed in the context of a recently published study investigating daily evolution of monocyte HLA-DR with regard to 28 day-mortality after severe sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.